(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2 days till quarter result
(bmo 2024-04-29)
Expected move: +/- 0.00%
-0.25% € 23.79
Live Chart Being Loaded With Signals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...
Stats | |
---|---|
Volumen de hoy | 70 820.00 |
Volumen promedio | 92 922.00 |
Capitalización de mercado | 134.31B |
EPS | €0 ( 2024-01-30 ) |
Próxima fecha de ganancias | ( €0 ) 2024-04-29 |
Last Dividend | €0.410 ( 2023-07-27 ) |
Next Dividend | €0 ( N/A ) |
P/E | 69.96 |
ATR14 | €0.0470 (0.20%) |
Volumen Correlación
Pfizer Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pfizer Inc Correlación - Moneda/Commodity
Pfizer Inc Finanzas
Annual | 2023 |
Ingresos: | €58.50B |
Beneficio Bruto: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2023 |
Ingresos: | €58.50B |
Beneficio Bruto: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2022 |
Ingresos: | €100.33B |
Beneficio Bruto: | €65.99B (65.77 %) |
EPS: | €5.63 |
FY | 2021 |
Ingresos: | €81.29B |
Beneficio Bruto: | €50.47B (62.08 %) |
EPS: | €3.95 |
Financial Reports:
No articles found.
Pfizer Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.400 (N/A) |
€0.400 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.410 | 2023-07-27 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 68 | -- |
Total Paid Out | €20.64 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.7 | -- |
Div. Sustainability Score | 6.07 | |
Div.Growth Potential Score | 4.08 | |
Div. Directional Score | 5.07 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WCH.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
FPE3.DE | Ex Dividend Knight | 2023-05-04 | Annually | 0 | 0.00% | |
PAT.DE | Ex Dividend Junior | 2023-05-26 | Sporadic | 0 | 0.00% | |
AXA.DE | Ex Dividend Junior | 2023-05-08 | Sporadic | 0 | 0.00% | |
HHFA.DE | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
S9I.DE | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% | |
CGN.DE | Ex Dividend Knight | 2023-09-05 | Quarterly | 0 | 0.00% | |
KHNZ.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
TLX.DE | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
DUE.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0367 | 1.500 | 9.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00947 | 1.200 | 9.68 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0222 | 1.500 | -0.864 | -1.296 | [0.1 - 1] |
payoutRatioTTM | 4.31 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.907 | 0.800 | -0.467 | -0.373 | [1 - 3] |
quickRatioTTM | 0.583 | 0.800 | -1.279 | -1.023 | [0.8 - 2.5] |
cashRatioTTM | 0.0597 | 1.500 | -0.779 | -1.169 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.18 | [0 - 0.6] |
interestCoverageTTM | 0.551 | 1.000 | -0.907 | -0.907 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.57 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.796 | -1.500 | 6.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.479 | 1.000 | 5.36 | 5.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0208 | 1.000 | -1.584 | -1.584 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.123 | 1.000 | -0.429 | -0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.258 | 0.800 | -1.612 | -1.289 | [0.5 - 2] |
Total Score | 6.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 66.39 | 1.000 | 3.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0222 | 2.50 | -0.555 | -1.296 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.71 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 6.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 4.31 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -2.39 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.149 | 1.000 | 8.78 | 0 | [0.1 - 0.5] |
Total Score | 4.08 |
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico